Open this publication in new window or tab >>Show others...
2020 (English)In: Cancers, ISSN 2072-6694, Vol. 12, no 3, article id 753Article in journal (Refereed) Published
Abstract [en]
Nearly half of all cancers are treated with radiotherapy alone or in combination with other treatments, where damage to normal tissues is a limiting factor for the treatment. Radiotherapy-induced adverse health effects, mostly of importance for cancer patients with long-term survival, may appear during or long time after finishing radiotherapy and depending on the patient's radiosensitivity. Currently, there is no assay available that can reliably predict the individual's response to radiotherapy. We profiled two study sets from breast (n = 29) and head-and-neck cancer patients (n = 74) that included radiosensitive patients and matched radioresistant controls. We studied 55 single nucleotide polymorphisms (SNPs) in 33 genes by DNA genotyping and 130 circulating proteins by affinity-based plasma proteomics. In both study sets, we discovered several plasma proteins with the predictive power to find radiosensitive patients (adjusted p < 0.05) and validated the two most predictive proteins (THPO and STIM1) by sandwich immunoassays. By integrating genotypic and proteomic data into an analysis model, it was found that the proteins CHIT1, PDGFB, PNKD, RP2, SERPINC1, SLC4A, STIM1, and THPO, as well as the VEGFA gene variant rs69947, predicted radiosensitivity of our breast cancer (AUC = 0.76) and head-and-neck cancer (AUC = 0.89) patients. In conclusion, circulating proteins and a SNP variant of VEGFA suggest that processes such as vascular growth capacity, immune response, DNA repair and oxidative stress/hypoxia may be involved in an individual's risk of experiencing radiation-induced toxicity.
Place, publisher, year, edition, pages
MDPI AG, 2020
Keywords
radiosensitivity, prediction, plasma proteins, radiotherapy, breast cancer, head-and-neck cancer, skin reaction, biomarker, mandibular osteoradionecrosis, ionizing radiation, radiotherapy side effects, personalized radiotherapy
National Category
Pharmaceutical and Medical Biotechnology
Identifiers
urn:nbn:se:kth:diva-276660 (URN)10.3390/cancers12030753 (DOI)000530232300229 ()32235817 (PubMedID)2-s2.0-85082510288 (Scopus ID)
Funder
Science for Life Laboratory - a national resource center for high-throughput molecular bioscience
Note
QC 20200622
2020-06-222020-06-222025-02-17Bibliographically approved